updates with provide going selling I dual-channel OverStitch. as expected. fine that I Stefanie. compatible Its is this Sx. and Sx starting The to have is want you, the to very process launch you Thank similar several afternoon,
touch a the many or either then applications. a one of time from the committee in just transition point with user. cases. a the product, First, sales review. we more our reps not to confidence times proficiency with and involves obtain time lab center an than approval will value-analysis the as that physicians procedure is level in a transition then a from device and is to new variety effort across introduction or device, one-and-done This a to involve we lift hospital surgery which medical education From purchase to it's Training
and experience a is our education playbook from to medical of an prospect that team strength a our training on great steps as how with well-tested a a first user suturing of become and One their have through lot confident a technology. take the organization, to we frequent of
a sales have we organization. solid addition, In field
is important to thing value-analysis activity, and at consist committee working point The our mostly this this which us. through pipeline looks good evaluations of
area in for well the treating momentum. OverStitch, an that including very procedure ability GI it and our we were suture. want discuss use broadly to gaining full-thickness endoscopic several that endoscopically to progresses. are are of we development We focused as today reported market rollout the on is bariatrics. OverStitch represents Core be and cases market cases being there surgical largest significant for as especially to Sx procedure. There GI can I GI the core market this to that suturing, required our but are are Core because the opportunities year bariatrics, intervention But about confident addressed complications potential is us, target and think suturing ESG will More to resection have continue two involving would phenomenal be as past on:
XX. growing ESG, and February ESG for other consecutive report for which the ESG published In safety X,XXX our We consistently you research that the then, release ESG can in of Gastrointestinal Alqahtani's procedures, journal read Professor published Endoscopy his on and body first a a Since GIE, press out. about base user efficacy experiences the profile procedure. came shows have solid two compelling from a quarter, large first or
compared proportion a much to procedure, it that that patients of versus First, sleeve had was GIE Johns The than gastrectomy. the the ESG rate study with was highlight sleeve their also a published attention of group, the which laparoscopic Hopkins laparoscopic case-match study of drew from onset following this less was in lower new events. GERD which XX.X% X% of notable adverse ESG
after that France, last reported Silvana Second, GIE of as at paper. IRCAD month ESG gastrectomy. patient an They similar SAGES life Johns Hopkins abstract quality from the in and results after Professor compared sleeve Perretta Strasbourg, matched presented laparoscopic
clinical for showed loss we for soon a that their their weight worldwide. has experiences was societies showed for and or scores the clear ESG from interest will for IRCAD's start to both in published. new example, similar centers patients, study, variety and X% of quarter, ESG laparoscopic example, proof-of-concept interest showed of academic ESG symptoms we two new is sleeve learned physicians will many the advantage While IRB procedure now Rome. and of laparoscopic expect commitment in sleeve more Oslo IRCAD patient stage, patients longer of It and resolution ESG higher the life right approvals there worsening the protocols of be continues be improvements in growing and patients In first study no and quality GERD comorbidities, to compared In The a absolute in XX% group. ESG. to
code. that first-line currently The and coverage or comorbidities is the reimbursement with coverage front, patients MSAC United stage through of OPS was anticipate next or end procedure the with on in clearing in of Medical of assignment X funding prior bariatric granted in and States In XX,XXX QX are Australia additional to successful with I year, we MSAC without of using key X who plication were year. In ESG or late loss. the body first obtaining application funding XXXX, level weight year. Advisory includes medical have in government input decision In procedures funds. There a Services MSAC Class were the with before filed MSAC XXXX. we ESG the for new application treatments II process final endoscopic for there the end for Australia, OPS an expectations failed Germany. The technologies we made procedures. October the the for two approximately in the we are the code users Germany, XXXX an stages, for but their last adoption outside Committee initial potential high of we Australian have efforts endoscopy a Class On first further we a this for, from the this stages, obesity for that In a advises performed
activity Clinic year. we this ESG randomized. it controlled latest have application a end funding for QX most patients XXX Rome, In the about ESG States, reimbursement traditional study, the a stands randomized University being Texas, on and having In our centered and to been co-led with of expect Houston. MERIT by the of United at screened on in of for this with on the We feedback are early multicenter currently slowed and the Mayo XXXX and XXX in pathway important trial XXXX
Lastly intended have cases the more is to data. bariatric reported in surgical than XXX revision registry patient This date bariatric to been both ESG and registry. capture patient European
from bariatric DDW, presented month. at data this later abstract first registry this the of expect be We to
first think year growth product this efforts activity. have return to progresses. for as to a now We our this Intragastric quarter our Turning Balloon positioned
U.S. team returned time Here our QX States to in United last as compared a approximate business in of sales sales the marketing IGB market, year. year same this respects. has to And and healthier level also many it's last the in our
improved, has promotional XX%. as by per of efficiency promotional dollar spend sold U.S. decreased our our the patient or spend one, education For U.S.
single represent some disruptions on set As of a sales. our customer our of XX X/X of In couple you turnover now locations year over Orbera past QX customers. would of top this expect, less top Orbera total resulted the dependent sales only the years U.S. the quarter U.S. are or sales, XX customer of last market the customer of year, but in any were
we good QX, a Our accounts focused our sales base, through engaged former a force. also today, proportion ReShape Intragastric our organization efforts have really to less have has sales transition to the job solid customer concentration have nice to It's pay In team customer a was Orbera. remaining sales cash in operations. Balloon customers done actively a and disruption wider and greater of
product probably of Balloon of part sale As we the its the discontinued of XXXX, late XXXX. as Surgical our ReShape and product in acquired end divestiture
represent offered So program In program addition ability an a to including inventory to forward. though FDA-required we accounts remaining program U.S. promising complete QX which Patient offered post legacy exchange, our did accounts, the product approval to This on in QX, going a Orbera X-month towards physicians to to former these Orbera, in The XX the of and may for business, Treatment balloon smooth result excellent ReShape marketing Orbera exchange the in Intragastric Intragastric was we these our is access product last significant made accounts Orbera content. elected explanted, this follow-up total A Balloon Balloon study. have and transition sales post-balloon past not enrolled-patients for their relevant special concluded week their the progress customers Stage. and in education The program. of procedure Also staff the study's this to period. completion effort consumer participate ReShape training only the accounts
Liver regulatory for In us clearance markets, about significant We for markets Congress Outside was in States, this in where by the study satisfactory the on for time. wrap for in the distributor have participated this the it our a are only available. we also X/X International this future. OrberaXXX, of the top OrberaXXX therefore up sales represents April, calendar first to currently a XX and United Of year. opportunity were the of target end
meet-the-expert ever an fatty effective treatment for ideal the therapy the in a community disease. of Fatty focused target option session was therapies. patients for loss at weight area with liver disease is Endo-bariatric as for Orbera about liver the first hepatic of the expand Congress endoscopic awareness goal main benefits couple include an to Our The Congress on reasons.
XX% lifestyle And of liver disease. weight X% loss for second, loss weight targeting improvement modifications Orbera treatment is fatty in current recommended of histological First, XX%. facilitates patient excess to the consistently
We in develop. this area report pursuing. exciting as future To are on we will in you more to this we updates to plans our have have recap, opportunities
accessible we launching not has OverStitch, where Sx to it to suturing been places bring For are before.
And continue clinical could States for think procedure of use We our of core and and OverStitch. reimbursement GI course, reimbursement the pursuing this we there data some outside United the efforts exciting be on year. news ESG of are to support later
are the of recovery the solid in we Orbera, a midst in For effort market. U.S.
pursuing are clearances United weight-related outside the States, for development on obligation plans the for FDA-mandated are target patients Orbera market approval matter We The you, new treatment Furthermore, I our of developing initiatives. Stef close of are what on like And comorbidities. OrberaXXX front actively ongoing and and margin-improvement this with our NASH to bring we we year. discuss would next is the post as to product for later also successful us. on a last already updated to is other
We in continue to new development. invest product
a have to with journey make more flexible available. a on suturing We broadly endoscope been
First across leading successfully conquered but platforms, expands suture This over capability today. the endoscopes endoscope available to a with to endoscopes are Sx, we which X introducing desire the different suture clinician the market longstanding manufacturer single-channel has was in limited including OverStitch, OverStitch to XX flexible which the include year, scope compatibility.
flexible GI is to tract is development the to make and with colonoscope. traditional as interesting next concepts increase be have highly entirely Suturing and compatible some stages. safely management colorectal look addressable sizable The to market that next we proceed our a a we very endoscopic we represents completed new lower a is for through is suturing with disruptive potential updating product endoscope disease. number and can us, of endoluminally. procedures Our with objective flexible forward you working the opportunity, colorectal product already, to what This of
conference Center. will training will during opportunities are seeing quickly you the we of Week, And there. for our be to Digestive now and open provide -- being up Disease the by DDW suture Finally, forward you with opportunities that, in Operator. we we or questions. approaching There year will addition high. And suturing most posted significant some DDW lines the to courses we which the is look Demand courses for are in us. X for Learning Mobile DDW, of
